Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2014

Feb 14, 2014

30291_dirs_2014-02-14_0aab24b7-b8b3-4307-bf69-4dbf7a702146.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2014-02-12

Reporting Person: Kingsley Stuart A (EVP, Global Comm. Operations)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-02-12 Common Stock M 2246 Acquired 12998 Direct
2014-02-12 Common Stock F 1059 $323.04 Disposed 11939 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-02-12 Restricted Stock Unit $0 M 2246 Disposed 2017-02-12 Common Stock (2246) Direct
2014-02-12 Restricted Stock Unit $0 A 6670 Acquired 2017-02-12 Common Stock (6670) Direct

Footnotes

F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

F2: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).